Orchard Therapeutics develops hematopoietic stem cell (HSC) gene therapies to treat severe genetic diseases, such as metachromatic leukodystrophy. Their platform aims to provide long-term therapeutic benefits by addressing the underlying genetic causes of these conditions.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe genetic diseases, such as metachromatic leukodystrophy (MLD), often lack effective treatments that address the underlying genetic cause, leading to significant morbidity and mortality. Current therapies may only manage symptoms without providing a long-term cure.
Solution
Orchard Therapeutics develops hematopoietic stem cell (HSC) gene therapies designed to provide long-term therapeutic benefits for patients with severe genetic diseases. Their platform involves modifying a patient's own HSCs with a functional copy of the defective gene. These modified cells are then transplanted back into the patient, where they engraft in the bone marrow and produce the missing protein or enzyme, addressing the root cause of the disease. This approach aims to provide a durable, potentially curative effect with a single treatment.
Target Audience
The primary target audience includes patients with severe genetic diseases, such as metachromatic leukodystrophy, and their families, as well as healthcare providers specializing in gene therapy and inherited metabolic disorders.
Features
- Utilizes patient's own HSCs to minimize the risk of immune rejection.
- Employs gene transfer technology to deliver a functional gene copy into HSCs.
- Targets the underlying genetic cause of severe inherited diseases.
- Aims for long-term protein or enzyme production from modified HSCs.
- Designed to provide a potentially curative effect with a single administration.